Expertise in
2
conditions

Dirk Niemann

Gemeinschaftsklinikum Mittelrhein
Koblenz, RP, DE 
Expertise in
2
conditions
Gemeinschaftsklinikum Mittelrhein
Koblenz, RP, DE 

Overview

Dirk Niemann practices practicing medicine in Koblenz, Germany.

Mr. Niemann is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, and Acute Promyelocytic Leukemia.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Gemeinschaftsklinikum Mittelrhein
Koblenz, RP, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 16, 2026
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3

13 Total Publications

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.
Journal: American journal of hematology
Published: August 18, 2025

Frequently Asked Questions about Dirk Niemann

Is Dirk Niemann a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dirk Niemann is classified as an Advanced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dirk Niemann participate in research or clinical trials?

Yes. Dirk Niemann has published 13 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dirk Niemann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Niemann's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile